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Abstract: There are currently no approved disease-modifying therapies for diabetic neuropathy, 
and there are only 3 US Food and Drug Administration-approved therapies (pregabalin, duloxetine, 
and tapentadol) for painful diabetic neuropathy. They each have moderate efficacy with adverse 
effects limiting optimal dose titration. There is a considerable need for new therapies for the 
management of painful diabetic neuropathy. We reviewed the potential role of mirogabalin, which 
like gabapentin and pregabalin modulates the alpha-2/delta-1 subunit of the voltage-gated calcium 
channel, allowing the influx of calcium and release of neurotransmitters at the synaptic cleft in 
the central nervous system and spinal cord. It has shown efficacy and good tolerability in a Phase 
II study in diabetic painful neuropathy and based on the results of two Phase III clinical trials in 
diabetic painful neuropathy and post-herpetic neuralgia, Daiichi Sankyo submitted a marketing 
application for neuropathic pain in Japan in February 2018. We have also reviewed potential new 
therapies, currently in Phase II clinical trials that may modify disease and/or relieve neuropathic 
pain through novel modes of action.
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Introduction
Diabetic peripheral neuropathy (DPN) is among the most frequently encountered long-
term complications of diabetes and has a prevalence of at least 50%.1,2 It is characterized 
by small and large fiber dysfunction and damage as a consequence of metabolic and 
vascular risk factors. DPN remains an unmet need for both patients and physicians and 
is a primary driver of physical and psychological comorbidity. Indeed, both quality 
of life and economic burden associated with DPN are significant and moreover, it is 
strongly associated with mortality.3–5 Several phenotypic variants of diabetic neuropathy 
have been recognized, but the most common is distal symmetrical polyneuropathy, 
an ascending neuropathy occurring in a glove and stocking distribution accounting 
for ∼75% of diabetic neuropathies.6 The symptoms in DPN are often related to small 
nerve fiber dysfunction and manifest as pain and dysesthesia, classically described 
as an unpleasant “burning”, “shooting”, “prickly”, and “excruciating” pain, typical 
of neuropathic pain.7,8 Painful DPN is particularly difficult to manage and although a 
number of agents are available, optimal pain control is inadequate.5,9
Current therapies
There are no FDA-approved disease-modifying therapies for DPN. Optimizing gly-
cemic control remains the most broadly accepted approach to prevent the progression 
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of neuropathy with moderate benefit in patients with Type 
1 diabetes,10 but with limited benefit in Type 2 diabetes.11 
Simultaneous pancreas and kidney transplantation restores 
normoglycemia and renal function and may reverse DPN.12
Controlling pain in diabetic neuropathy
Neuropathic pain is a debilitating feature of DPN resulting 
in significant morbidity.5,13 Although tight glycemic control 
may prevent the progression of diabetic neuropathy, there is 
a paucity of data suggesting that improved glycemic control 
improves pain in DPN.14 Moderate improvements in pain are 
considered to be ∼30%–50% pain relief, whereas >50% pain 
relief is considered a good outcome.15 Unfortunately, painful 
DPN responds poorly to conventional analgesics, but tend to 
be frequently used especially in primary care settings.16 Guide-
lines do not recommend nonsteroidal anti-inflammatories due 
to their lack of efficacy and propensity to deteriorate renal 
function.9 Currently, five professional organizations have pro-
duced expert guidance on the management of painful diabetic 
neuropathy.8,17–21 Medications recommended include tricyclic 
antidepressants (TCAs), serotonin-norepinephrine reuptake 
inhibitors (SNRIs), or γ-aminobutyric acid (GABA) analogs 
(gabapentin or  pregabalin) as first-line agents  followed by 
opioids and topical treatments. The only two medications 
with both FDA and European Medicines Agency (EMA) 
approval for the treatment of painful DPN are pregabalin and 
duloxetine. Recently, the COMBO-DN study has shown the 
effectiveness of a combination of duloxetine and pregabalin 
in painful DPN.22
Tricyclic antidepressants
Developed initially for depression, TCAs are commonly used 
as analgesics for neuropathic pain in contemporary clinical 
practice. The exact mechanism promoting analgesia in pain-
ful DPN is still not precisely known, but they are known to 
act through a number of pathways, with antagonistic actions 
at the N-methyl-D-aspartate, 5-HT, histamine, muscarinic, 
and α-adrenergic receptors while also blocking the reuptake 
of noradrenaline and serotonin from synaptic clefts23 as well 
as indirect modulation of the opioid system in the brain.24–26 
The use of TCAs is limited by their adverse effect profile.27
Serotonin-norepinephrine reuptake 
inhibitors
The SNRIs exert their analgesic effects by altering the bal-
ance of neurotransmitters centrally and through stimulation 
of descending inhibitory pathways by selectively antago-
nizing the effects of both serotonin and norepinephrine.28 
Duloxetine was the first agent to be approved by the FDA 
for the treatment of diabetic painful neuropathy based on 
data from several large randomized controlled trials.29–33 
Goldstein et al demonstrated that doses of 60 and 120 mg 
of duloxetine were associated with an improvement in aver-
age daily pain scores in a randomized, placebo-controlled 
trial in 457 patients.31 More recently, Lunn et al conducted a 
Cochrane review, analyzing data from eight different studies 
(n=2,728), comparing duloxetine to placebo.29 They reported 
that doses of 60 and 120 mg of duloxetine were associated 
with a significant improvement in neuropathic pain in DPN. 
The adverse effect profile of duloxetine is more favorable 
compared with TCAs, with fewer anti-muscarinic adverse 
effects.34,35 Patients treated with duloxetine were found to 
have slight weight gain and raised fasting glucose levels, 
although to a lesser extent than with pregabalin.36 Duloxetine 
is considered to be more cost-effective than pregabalin and 
was approved for the treatment of diabetic painful neuropathy 
by National Institute for Clinical Excellence.
GABAA α2δ subunit
The α2δ subunit (α2δ-1 and α2δ-2) of voltage-sensitive 
calcium channels in the central nervous system (CNS) 
has been utilized as the molecular target for pain relief in 
neuropathic pain. The FDA and EMA have approved pre-
gabalin as first-line treatment for painful DPN.19,37,38 Both 
pregabalin and gabapentin act as a nonselective ligand at 
the α2δ-1 and α2δ-2 subunits. The structure of these chan-
nels is composed of a central pore-forming alpha-1 subunit, 
a disulfide-linked glycoprotein consisting of α2δ subunits 
and intracellular beta subunits. Enhanced understanding of 
the α2δ subunits has suggested that α2δ-1 and α2δ-2 may 
in fact have different clinical effects.39,40 Binding to α2δ-1 
may contribute to analgesic effects, whereas binding to α2δ-2 
appears to contribute to undesirable CNS effects such as som-
nolence.37,41,42 Additional experimental studies have shown 
that GABAA receptors containing α2δ-2 and α2δ-3 subunits 
are crucial components of spinal pain control. Defining the 
precise role of GABAA receptor subtypes remains a key area 
for therapeutic advancement to ensure that novel GABA 
modulators are developed as a potential new therapeutic 
area for chronic neuropathic pain.39,40 More recently, it has 
been suggested that GABAA α5 receptors play a role in the 
loss of GABAergic inhibition and contribute to long-lasting 
secondary allodynia and hyperalgesia,43 and antagonism of 
GABAA α2δ-5 leads to reversal of impaired rate-dependent 
depression of the Hofmann reflex, a potential biomarker 
for spinally mediated pain secondary to loss of GABAergic 
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inhibition in diabetes.44,45 AZD7325 is a novel partial α2δ-2,3 
subtype-selective GABAA receptor modulator with minimal 
in vitro efficacy at the α2δ-1 and α2δ-5 receptor subtypes 
and produces anxiolytic effects in humans associated with 
selective GABAA α2δ-2,3 agonism.46 There was increased 
expression of GABAA α2δ-1 mRNA and α2δ-1 protein in 
the dorsal root ganglion and dorsal horn of rat models of 
neuropathic pain.47 Transgenic mice with elevated neuronal 
expression of the α2δ-1 subunit exhibited hypersensitivity 
to both tactile allodynia and thermal hyperalgesia and elec-
trophysiological hyperexcitability in the dorsal root ganglion 
and spinal cord.48 Gabapentin blocked voltage-gated calcium 
channel currents in a concentration-dependent manner in 
these transgenic mice.48 The role of GABAA subtypes in 
promoting analgesia is complex and requires further study.
Gabapentin
Widely prescribed for diabetic neuropathy, gabapentin 
inhibits the presynaptic calcium channel at the α2δ ligand.49 
Backonja et al randomized patients in a ratio of 1:1 to receive 
either gabapentin or placebo and reported a number needed 
to treat (NNT) of 3.7 to achieve 50% pain relief after 8 weeks 
of treatment.50 Since then several studies have confirmed 
the efficacy of gabapentin for neuropathic pain.51–57 Several 
systematic reviews have found a significant analgesic effect 
of gabapentin in neuropathic pain27,58 and a Cochrane Col-
laboration review on gabapentin reported an NNT of 5.9 for 
the relief of neuropathic pain.59 Rudroju et al compared the 
efficacy and safety of a number of drugs in painful DPN and 
concluded that gabapentin offered the most favorable balance 
of safety and efficacy.27
Pregabalin
Pregabalin has higher reported potency due to higher 
absorption and affinity for the α2δ1 subunit. The efficacy 
of pregabalin in painful diabetic neuropathy has been estab-
lished in four double-blind placebo-controlled trials,60–63 and 
a recent meta-analysis found that pregabalin was the most 
efficacious agent for the management of painful DPN when 
patients were asked to grade their level of pain on a visual 
analog scale.64 It exhibits a dose-dependent response, with 
600 mg being associated with the greatest analgesic effect, 
improved mood, and less sleep interference. Sicras et al 
also reported that pregabalin was associated with reduced 
healthcare costs in a cost- comparative analysis of patients 
treated with pregabalin and gabapentin.65 Weight gain can 
be an issue with pregabalin, and in a pooled analysis of 41 
trials (n=3,187) while the majority of patients treated with 
pregabalin (150–600 mg/day) for 1 year maintained weight 
within ±7% of their baseline weight, one in six patients gained 
≥7% weight from baseline within 2–12 months of commenc-
ing treatment.36 Patients should also be warned against abrupt 
discontinuation of pregabalin, as this has been associated with 
encephalopathy and cerebral edema, and there is the issue of 
recreational abuse amongst illicit drug users.66,67
Combination therapy
The COMBO-DN study was designed to compare the effi-
cacy and tolerability of high-dose monotherapy (duloxetine 
120 mg daily or pregabalin 600 mg daily) to standard dose 
combination therapy (duloxetine 60 mg and pregabalin 300 
mg daily) in patients with painful DPN who were resistant 
to standard dose monotherapy.22 There was no significant 
difference between standard dose combination therapy and 
high-dose monotherapy.22 In a secondary analysis, duloxetine 
60 mg/day was superior to pregabalin 300 mg/day in the 
initial 8-week run-in phase, and this remains the only head-
to-head trial of pregabalin and duloxetine.
Other anticonvulsants
Other anticonvulsants such as lamotrigine and topiramate 
have been studied in painful diabetic neuropathy. A Cochrane 
review analyzed four trials of lamotrigine in painful DPN 
and found no evidence of its efficacy.68,69 Trials evaluating 
topiramate have reported similar conflicting findings.64,70,71 
Although Raskin et al reported that topiramate was effica-
cious in the management of painful diabetic neuropathy, 
Thienel et al reported that a number of smaller studies had 
not shown any benefit.70,71 It is evident that achieving adequate 
pain relief in painful DPN remains difficult for many patients 
and adequate analgesia may require combination therapy. The 
need for new more effective agents is apparent.
The case for mirogabalin
Mirogabalin and pregabalin were recently compared in partial 
sciatic nerve ligation and streptozotocin-induced diabetes.47 
Mirogabalin showed more selective binding affinity for the 
human and rat α2δ subunits, with a slower dissociation for 
the α2δ-1 subunit compared with the α2δ-2 subunit and hence 
potent analgesia with less CNS side effects.
Pharmacokinetics
The pharmacokinetics of mirogabalin has been studied 
extensively in healthy subjects with doses ranging from 3 to 
75 mg (data on file, Daiichi Sankyo).72 Following oral admin-
istration, maximum plasma concentration of mirogabalin is 
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achieved at ~1 hour.72 The area under the plasma concen-
tration-time curve and maximum plasma  concentration are 
proportional with higher doses.72 The plasma protein binding 
of mirogabalin is relatively low at ∼25% in humans.72 The 
drug is largely renally excreted and undergoes minimal in 
vivo metabolism.72 A multicenter open-label study assessed 
the pharmacokinetics and safety of a single dose of 5 mg 
mirogabalin in 30 participants with normal, mild, moderate, 
or severe renal impairment.73 The plasma concentration-
time curve increased with severity of renal impairment.73 A 
statistical model detailing the population pharmacokinetics 
of mirogabalin in relation to varying degrees of renal impair-
ment has been developed and identified an effect on renal 
and nonrenal clearances of mirogabalin.72 The simulation 
suggested reducing the dose of mirogabalin by 50% in people 
with moderate renal impairment and by 75% in people with 
severe renal impairment.72 A recent randomized, placebo-
controlled, double-blind, sequential, ascending-dose study 
evaluated single (10–40 mg) and repeated (10, 15 mg twice 
a day) doses of mirogabalin in Japanese, Korean, Chinese 
and White subjects and demonstrated comparable pharma-
cokinetic parameters.74
Clinical studies
Vinik et al conducted a multicenter, randomized, double-
blind, placebo- and active comparator-controlled, proof-of-
concept Phase II study.42 In this study, adults with diabetic 
painful neuropathy of 6 months or greater were randomized 
(2:1:1:1:1:1:1) to receive placebo, increasing doses of miro-
gabalin (5, 10, 15, 20, and 30 mg daily), and pregabalin 300 
mg daily for 5 weeks.42 The severity of pain was measured 
over 5 weeks with a meaningful effect described as a 1-point 
or greater change in average daily pain score (rated on a 
numerical scale of 0–10). A dose of 30 mg mirogabalin 
caused a reduction in average daily pain scores of 1 or greater, 
whereas 15 and 20 mg doses caused a statistically significant 
reduction in pain scores; this was not considered to be clini-
cally meaningful. Median time to meaningful pain relief was 
30, 16, 20, and 16 days in the mirogabalin 10, 15, 20, and 30 
mg/day groups, compared with 36 days in the placebo group 
(P<0.05 for all comparisons).
There were statistically significant differences in the change 
in the average daily pain score between pregabalin 300 mg and 
mirogabalin 15 and 30 mg. However, subjects in the pregabalin 
arm received 300 mg in divided doses and it remains unknown 
whether higher single doses would have affected efficacy. 
Second, the placebo response rate was higher than expected 
in this study as Freeman et al previously showed a placebo 
response of –1.47, whereas in the present study, it was –1.86.75 
This single study suggests that mirogabalin may have a role in 
the management of painful diabetic neuropathy. However, the 
unique design of the trial necessitates caution when comparing 
these data with other published trials.
In addition to efficacy, this Phase II trial assessed the 
safety of mirogabalin using adverse event (AE) data, clinical 
laboratory tests, and electrocardiograms. Most frequent AEs 
(n=277) were mild to moderate dizziness (9.4%), somnolence 
(6.1%), and headache (6.1%); otherwise, mirogabalin was 
well tolerated. Hutmacher et al carried out exposure-response 
modeling for mirogabalin with respect to pain scores and 
adverse effects and showed that the incidence of dizziness 
and somnolence decreased over time and twice-daily dosing 
of mirogabalin was predicted to yield a lower incidence of 
dizziness compared with once-daily dosing.76 Taken together, 
these findings suggest that the doses of mirogabalin can be 
titrated to achieve equivalent analgesic effect to pregabalin 
but with less adverse effects, particularly dizziness.76 While, 
mirogabalin was well tolerated in Japanese subjects with 
normal and mild to severe renal impairment, dizziness, som-
nolence, and vomiting were reported with greater frequency 
in those with end-stage renal disease. It is therefore likely 
that the dose of mirogabalin will need dose adjustment in 
patients with moderate to severe renal impairment. However, 
of note only 5 mg of mirogabalin was used, and as reported 
previously this dose is unlikely to demonstrate a clinically 
meaningful analgesic effect in painful DPN.42
Efficacy of mirogabalin compared with 
pregabalin, gabapentin, and duloxetine
In the absence of direct head-to-head trials and given the 
paucity of efficacy data on mirogabalin, any comparisons 
between agents must be made with caution. Vinik et al 
reported that the percentage of subjects who reported a ≥50% 
reduction in average daily pain scores were 20%, 29%, 39%, 
43%, and 44% after 5 weeks for 5, 10, 15, 20, and 30 mg of 
mirogabalin, respectively.42 In a Cochrane review by Moore 
et al, a ≥50% reduction in average daily pain scores was 
achieved in 41% of patients receiving 600 mg of pregabalin.77 
For gabapentin78 and duloxetine,29 a ≥50% reduction in pain 
was found in 38% and 40%, respectively (Table 1).
Aes of mirogabalin compared with 
pregabalin, gabapentin, and duloxetine
The frequency of CNS adverse effects was 14% in the miro-
gabalin group compared with 12% in the pregabalin group 
(39). Seven percent of patients in the mirogabalin group 
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were unable to continue with treatment compared with 4% 
in the placebo group. This compares favorably to duloxetine, 
where a Cochrane review of 18 trials (n=6,407) reported 
that ∼12.5% of patients had to discontinue duloxetine due 
to adverse effects.29 A similar 12% rate of discontinuation 
due to AEs has been reported for gabapentin.59 A Cochrane 
review of pregabalin reported treatment discontinuation due 
to AEs in 18%–28% of subjects, though most trials utilized 
600 mg of pregabalin.42,77
Mirogabalin has equivalent efficacy but may be a more 
tolerable therapeutic option for painful diabetic neuropathy 
based on a comparison of efficacy and AEs (Table 1).
Novel therapies in DPN
There has been increasing interest in agents that target the 
pathophysiology of diabetic neuropathy. Vincent et al recently 
reviewed a number of cellular targets that could be used to 
develop novel therapies for DPN.8,79 Manipulation of the 
temperature-sensitive transient receptor potential (TRP) 
channel on nociceptive neurons has been proposed as an 
attractive strategy in targeting the pain pathway, especially 
since TRPV1 desensitization by topical agonists such as 
capsaicin has been used for painful DPN.80 VEGF-derived 
peptides may also be utilized as a pathogenetic therapy in 
diabetic neuropathy.81,82 Ropper et al investigated VEGF for 
the treatment of diabetic neuropathy in a double-blind ran-
domized trial but failed to show efficacy.82 The angiotensin 
II type 2 receptor (AT2R) axis plays a substantial role in pro-
moting nociceptive signaling by stimulating hyperexcitability 
and persistent ectopic firing of first-order sensory neurons.83 
Though AT2R antagonists have been long developed, they are 
now being repositioned as treatments for painful neuropathy.84 
In a Phase IIa study, Rice et al demonstrated the efficacy and 
safety of EMA401, a small molecular AT2R antagonist, in a 
cohort of 182 patients with postherpetic neuralgia.85 Clinical 
trials are currently suspended following acquisition of the 
agent by Novartis.84,86
Mutations in the Nav1.7 sodium channel have recently 
been described in a significant proportion of patients with 
painful diabetic neuropathy.87 Numerous Nav1.7 antagonists 
are currently in development. Xenon402, a novel Nav1.7 
blocker, was found to be effective in erythromelalgia and it 
has been suggested that Nav1.7 blockers may be useful in 
other types of neuropathic pain.88,89
Intrathecal drugs can be delivered at high concentration 
into the cerebrospinal fluid, limiting systemic adverse effects.90 
Whilst intrathecal morphine and ziconotide are approved for 
intractable pain,91 they have not been evaluated in DPN. More-
over, one should be cautious in the implantation of intrathecal 
delivery systems in relation to myelitis and arachnoiditis92 and 
impaired wound healing in patients with diabetes.
Produced by cells under stress, erythropoietin (EPO) 
is known to antagonize the production of proinflammatory 
molecules and as a consequence promotes tissue regenera-
tion.93,94 In experimental models, EPO is known to amelio-
rate DPN, but its use in humans is precluded by tendency to 
cause thrombosis. ARA290 is a nonhematopoietic peptide 
synthesized from EPO, which selectively targets the innate 
repair receptor, downregulating inflammation, without the 
procoagulant effects of EPO.95 In a recent Phase II trial of 
ARA290 in patients with painful DPN, patients receiving 
ARA290 for 28 days reported a significant improvement in 
neuropathic symptoms compared with placebo.95,96 A recent 
analysis of patients with sarcoidosis and small fiber neuropathy 
treated with ARA290 using corneal confocal microscopy dem-
onstrated small nerve fiber repair, suggesting a pathogenetic 
role for ARA290.97 Moreover, Zhang et al demonstrated that 
ARA290 can specifically inhibit TRPV1 channel activity and 
relieve capsaicin-induced hypersensitivity, indicating a dual 
basis for the efficacy of this drug in diabetic neuropathy.98
Conclusion
The rising global burden of diabetes is spurring an increase 
in the prevalence of diabetic neuropathy and neuropathic 
pain. At present, there are no FDA-approved pathogenetic 
therapies for DPN and the efficacy of treatments for painful 
DPN is limited. Therefore, there is a major need for the devel-
opment of novel disease-modifying and analgesic therapies 
for diabetic neuropathy. The promising data on mirogabalin 
suggests that it may soon be the fourth drug to receive market 
approval for neuropathic pain.
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